A pharmaceutical company in Pennsylvania is launching a clinical trial of a potential vaccine for COVID-19…. But “a potential vaccine” is “an actual vaccine”.

Inovio announced the FDA’s’ approval of the test Monday and began administering the vaccine to volunteers by shot quickly thereafter. Its study will involve 40 volunteers from Philadelphia and Kansas City. Each volunteer will receive two doses of the vaccine four weeks apart.

Researchers expect to receive data from those tests sometime near the end of summer. Dr. Joseph Kim, the company’s CEO, has emphasizes their intention to move through this process swiftly. Dr. Kim plans to have 1 million doses available by the end of the year.

“When the new outbreak occurred, we applied our very innovative 21st Century platform, called DNA medicines platform, to COVID-19,” he explained. “By getting just the DNA sequence of the virus, we were able to fully construct our vaccine within three hours.”

Read that again.

“….we were able to fully construct our vaccine within three hours.”

Views: 9